CMPI Insider Trading Activity and SEC Form 4 Filings
CMPI insider trading summary
No open-market insider purchases or sales of Checkmate Pharmaceuticals, Inc. (CMPI) have been reported on SEC Form 4 in the past 12 months.
Latest CMPI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 16, 2022 | Corey S Goodman | 10% Owner | Sell | $1.0M (95,800 @ $10.45) |
| May 16, 2022 | venBio Global Strategic Fund II L.P. | 10% Owner | Sell | $1.0M (95,800 @ $10.45) |
| May 16, 2022 | venBio Global Strategic GP II, L.P. | 10% Owner | Sell | $1.0M (95,800 @ $10.45) |
| May 16, 2022 | Robert J Adelman | 10% Owner | Sell | $1.0M (95,800 @ $10.45) |
| May 16, 2022 | venBio Global Strategic GP II, Ltd. | 10% Owner | Sell | $1.0M (95,800 @ $10.45) |
| May 13, 2022 | venBio Global Strategic GP II, Ltd. | 10% Owner | Sell | $374K (35,850 @ $10.45) |
| May 13, 2022 | Corey S Goodman | 10% Owner | Sell | $374K (35,850 @ $10.45) |
| May 13, 2022 | venBio Global Strategic GP II, L.P. | 10% Owner | Sell | $374K (35,850 @ $10.45) |
| May 13, 2022 | venBio Global Strategic Fund II L.P. | 10% Owner | Sell | $374K (35,850 @ $10.45) |
| May 13, 2022 | Robert J Adelman | 10% Owner | Sell | $374K (35,850 @ $10.45) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.